- Home
- BRKRP vs BGMS Comparison
BRKRP vs BGMS Comparison
Compare BRKRP & BGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRKRP | BGMS |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | Malaysia |
| Employees | 11396 | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 5.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BRKRP | BGMS |
|---|---|---|
| Price | $290.70 | $0.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 969.0 | ★ 140.7K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $137.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $256.35 | $0.74 |
| 52 Week High | $419.83 | $6.70 |
Technical Indicators
Market Signals| Indicator | BRKRP | BGMS |
|---|---|---|
| Relative Strength Index (RSI) | 35.09 | 38.31 |
| Support Level | $289.57 | $0.74 |
| Resistance Level | $322.28 | $1.12 |
| Average True Range (ATR) | 2.84 | 0.06 |
| MACD | 0.68 | 0.01 |
| Stochastic Oscillator | 11.59 | 13.95 |
Price Performance
Historical ComparisonAbout BRKRP Bruker Corporation 6.375% Mandatory Convertible Preferred Stock Series A
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
About BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.